Compugen completes enrollment in MAIA-ovarian trial of COM701, readout due Q1 2027
The company also flagged a Phase 3 readout from partner AstraZeneca's rilvegostomig program in H2 2027 and said cash runway extends into 2029.
SEC filing
1 story
The company also flagged a Phase 3 readout from partner AstraZeneca's rilvegostomig program in H2 2027 and said cash runway extends into 2029.
SEC filing